0,05. Доказательная медицина от магии до поисков бессмертия Талантов Петр
Geller A. I., Shehab N., Weidle N. J., Lovegrove M. C., Wolpert B. J. et al. Emergency department visits for adverse events related to dietary supplements // The New England Journal of Medicine. 2015. October 15. Vol. 373. P. 1531–1540.
Gregory P. Availability of DMAA supplements despite US food and drug administration action // JAMA Internal Medicine. 2013. Vol. 173. № 2. P. 164–165.
Zhang Y., Woods R. M., Breitbach Z. S., Armstrong D. W. 1,3-Dimethylamylamine (DMAA) in supplements and geranium products: natural or synthetic? // Drug Testing and Analysis. 2012. Vol. 4. P. 986–990.
Lindeboom G. A. The story of a blood transfusion to a pope // Journal of the History of Medicine and Allied Sciences. 1954. October 1. Vol. 9. № 4. P. 455–459.
Kaiser J. Blood from young people does little to reverse Alzheimer’s in first test // Science. 2017. November 1.
Cooper D. K. C. A brief history of cross-species organ transplantation // Proceedings (Baylor University. Medical Center). 2012. January. Vol. 25. № 1. P. 49–57.
Bajic P., Selman S. H., Rees M. A. Voronoff to virion: 1920s testis transplantation and AIDS // Xenotransplantation. 2012. November-December. Vol. 19. № 6. P. 337–341.
Setchell B. P. The testis and tissue transplantation: historical aspects // Journal of reproductiveimmunology. 1990. August. Vol. 18. № 1. P. 1–8.
Wang H., Zhao Y., Ezcurra M., Benedetto A., Gilliat A. F., Hellberg J., Ren Z. et al. A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type C. elegans // npj Aging and Mechanisms of Disease. 2018. Vol. 4. Art. № 6.
Cheetham T. C., An J., Jacobsen S. J. et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency // JAMA Internal Medicine. 2017. Vol. 177. № 4. P. 491–499.
Basaria S., Coviello A. D. Travison T. G., Storer T. W., Farwell W. R. et al. Adverse events associated with testosterone administration // The New England Journal of Medicine. 2010. July 8. Vol. 363. № 2. P. 109–122.
Bhasin S., Cunningham G. R., Hayes F. J., Matsumoto A. M., Snyder P. J. et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline // The Journal of Clinical Endocrinology & Metabolism. 2006. June 1. Vol. 91. № 6. P. 1995–2010.
Rudman D., Feller A. G., Nograj H. S., et al. Effects of human growth hormone in men over 60 years old // The New England Journal of Medicine. 1990. Vol. 323. № 1. P. 1–6.
Swerdlow A. J., Cooke R., Beckers D., Borgstrm B., Butler G. et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study // The Journal of clinical endocrinology and metabolism. 2017. May 1. Vol. 102. № 5. P. 1661–1672.
Robida-Stubbs S., Glover-Cutter K., Lamming D. W., Mizunuma M. et al. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO // Cell metabolism. 2012. May 2. Vol. 15. № 5. P. 713–724.
Bhullar K. S., Hubbard B. P. Lifespan and healthspan extension by resveratrol // Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. 2015. June. Vol. 1852. № 6. P. 1209–1218.
Rousakis A., Vlassis A., Vlanti A., Patera S., Thireos G., Syntichaki P. The general control nonderepressible-2 kinase mediates stress response and longevity induced by target of rapamycin inactivation in Caenorhabditis elegans // Aging Cell. 2013. Vol. 12. № 5. P. 742–751.
Baur J. A., Pearson K. J., Price N. L., Jamieson H. A., Lerin C., Kalra A. et al. Resveratrol improves health and survival of mice on a high-calorie diet // Nature. 2006. November 16. Vol. 444. № 7117. P. 337–342.
Pearson K. J., Baur J. A., Lewis K. N., Peshkin L., Price N. L., Labinskyy N. et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span // Cell metabolism. 2008. August. Vol. 8. № 2. P. 157–168.
Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ‘French paradox’? // European Journal of Endocrinology. 1998. June. Vol. 138. № 6. P. 619–620.
Goldberg D. M., Yan J., Soleas G. J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects // Clinical biochemistry. 2003. February. Vol. 36. № 1. P. 79–87.
Law M., Wald N. Why heart disease mortality is low in France: the time lag explanation // BMJ. 1999. May 29. Vol. 318. № 7196. P. 1471–1480.
Vang O. What is new for resveratrol? Is a new set of recommendations necessary? // Annals of the New York Academy of Sciences. 2013. July. Vol. 1290. № 1. P. 1–11.
Vaziri H., Dragowska W., Allsopp R. C., Thomas T. E., Harley C. B., Lansdorp P. M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age // PNAS. 1994. October 11. Vol. 91. № 21. P. 9857–9860.
Jodczyk S., Fergusson D. M., Horwood L. J., Pearson J. F., Kennedy M. A. No association between mean telomere length and life stress observed in a 30 year birth cohort // PLoS One. 2014. Vol. 9. № 5, e97102.
Chae D. H., Nuru-Jeter A. M., Adler N. E., Brody G. H., Lin J., Blackburn E. H., Epel E. S. Discrimination, racial bias, and telomere length in African-American men // American journal of preventive medicine. 2014. February. Vol. 46. № 2. P. 103–111.
Jaskelioff M., Muller F. L., Paik J.-H., Thomas E., Jiang S., Adams A. et al. Telomerase reactivation reverses tissue degeneration in aged telomerase deficient mice // Nature. 2011. January 6. Vol. 469. № 7328. P. 102–106.
Sprouse A. A., Steding C. E., Herbert B.-S. Pharmaceutical regulation of telomerase and its clinical potential // Journal of cellular and molecular medicine. 2012. January. Vol. 16. № 1. P. 1–7.
Sanders J. L., Newman A. B. Telomere length in epidemiology: a biomarker of aging, age-related disease, both, or neither? // Epidemiologic Reviews. 2013. January 1. Vol. 35. № 1. P. 112–131.